Sugi Predict

Sugi Predict / Compounds / SCHEMBL3136682

SCHEMBL3136682

SCHEMBL3136682

Nc1nc2ccc(Br)c(F)c2s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 1/20 0.44
▸ GFER P55789 1/20 0.44
▸ MAPT P10636 3/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ SCN4A P35499 3/20 0.38
▸ EPHX2 P34913 1/20 0.38
▸ SMN1; SMN2 Q16637 6/20 0.37
▸ RAB9A P51151 6/20 0.37
▸ GAA P10253 2/20 0.37
▸ HTT P42858 2/20 0.37
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ NPC1 O15118 5/20 0.35
▸ TP53 P04637 2/20 0.35
▸ LMNA P02545 2/20 0.35
▸ CYP1A2 P05177 2/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ PKM P14618 2/20 0.35
▸ HSD17B10 Q99714 2/20 0.35
▸ KCNH2 Q12809 1/20 0.35
▸ GMNN O75496 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17839739 0.82 PLK4 (0.30) MAPK1
SCHEMBL17609992 0.81 AXL (0.47) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL8379060 0.81 MAPT (0.45) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL12596659 0.78 RAB9A (0.44) MAPTALDH1A1SMN1; SMN2RAB9AGAA
SCHEMBL17610010 0.78 SMN1; SMN2 (0.52) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL25338656 0.78 GAA (0.44) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL12210717 0.78 SMN1; SMN2 (0.43) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL659725 0.78 AXL (0.44) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL25423809 0.78 SMN1; SMN2 (0.44) AXLGFERMAPTALDH1A1SCN4A
SCHEMBL3146829 0.78 SMN1; SMN2 (0.44) AXLGFERMAPTALDH1A1SCN4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4658656-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES Beone Medicines I GmbH (CH) 2025-12-10 — — EP disclosed
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEONE MEDICINES I GMBH (CH) 2025-11-13 — — US disclosed
US-12162871-B2 Inhibitors of VAP-1 ACUCELA INC. (US) 2024-12-10 — — US disclosed
EP-4457224-A1 HETEROCYCLIC COMPOUNDS BeiGene Switzerland GmbH (CH) 2024-11-06 — — EP disclosed
US-20240327417-A1 HETEROCYCLIC COMPOUNDS BEIGENE SWITZERLAND GMBH (CH) 2024-10-03 — — US disclosed
WO-2024160276-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES BEIGENE, LTD. (KY) 2024-08-08 — — WO disclosed
CN-118451073-A Heterocyclic compounds 百济神州有限公司 2024-08-06 — — CN disclosed
US-11787791-B2 Inhibitors of VAP-1 ACUCELA INC. (US) 2023-10-17 — — US disclosed
US-11787791-B2 Inhibitors of VAP-1 ACUCELA INC. (US) 2023-10-17 — — US disclosed
US-11787791-B2 Inhibitors of VAP-1 ACUCELA INC. (US) 2023-10-17 — — US disclosed
EP-3233850-B1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2019-04-03 — — EP disclosed
US-9751874-B2 Hydroxy containing FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2017-09-05 — — US disclosed
US-9751874-B2 Hydroxy containing FXR (NR1H4) modulating compounds GILEAD SCIENCES, INC. (US) 2017-09-05 — — US disclosed
US-20160176861-A1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2016-06-23 — — US disclosed
US-20160176861-A1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2016-06-23 — — US disclosed
WO-2016096115-A1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS GILEAD SCIENCES, INC. (US) 2016-06-23 — — WO disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 — — US disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 — — US disclosed
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG 2010-03-25 — — US disclosed
WO-2007095588-A1 PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2007-08-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11787791-B2 Inhibitors of VAP-1 VAPB, VAPA, TOE1 AXL 3652/4885GFER 3671/4885MAPT 2213/4885
US-20240327417-A1 HETEROCYCLIC COMPOUNDS NFATC1, CD4, ACIN1 AXL 3417/4885GFER 4756/4885MAPT 3912/4885
US-20100075965-A1 PI3 KINASE INHIBITORS AND METHODS OF THEIR USE PIK3CA, PIK3CD, PIK3CB AXL 702/4885GFER 4037/4885MAPT 4111/4885
US-12162871-B2 Inhibitors of VAP-1 VAPB, VAPA, TOE1 AXL 3652/4885GFER 3671/4885MAPT 2213/4885
US-20250346597-A1 CONDENSED HETEROCYCLIC COMPOUNDS AS INHIBITOR OF DIACYLGLYCEROL KINASES DGKG, DGKA, DGKK AXL 3141/4885GFER 4337/4885MAPT 4168/4885
US-20160176861-A1 HYDROXY CONTAINING FXR (NR1H4) MODULATING COMPOUNDS NR1H4, NR1H3, NR1H2 AXL 2925/4885GFER 1732/4885MAPT 3116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.